Skip Navigation


JAC Advance Access originally published online on June 9, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/1/14    most recent
dkh319v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sarisky, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarisky, R. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy 2004 54(1):14-16; doi:10.1093/jac/dkh319
JAC vol.54 no.1 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.

Leading article

Non-nucleoside inhibitors of the HCV polymerase

Robert T. Sarisky*

Department of Virology, The Metabolic and Viral Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, PA 19426, USA

* Present address. Centocor, Inc., Infectious Diseases Research, 145 King of Prussia Road, Radnor, PA 19087, USA. Tel: +1-610-240-8207; Fax: +1-610-240-4064; Email: rsarisky{at}cntus.jnj.com

Chronic hepatitis C virus (HCV) infection is the leading cause of chronic liver disease. Current therapy using pegylated interferon-{alpha} with ribavirin is poorly tolerated and confers an overall sustained virological response around 56%. Compounds exhibiting an improved safety profile with similar or enhanced antiviral properties may represent future treatment options. Several drug discovery programmes are ongoing to directly target the viral enzymes involved in HCV replication. Recent clinical success using a peptidomimetic inhibitor of the viral serine protease has demonstrated proof-of-concept for the use of direct antiviral agents in reducing viral load. The RNA-dependent RNA polymerase (RdRp) of HCV is also required for viral RNA replication and thus represents an attractive drug discovery target. Preclinical characterization of several non-nucleoside inhibitors (NNIs) of the HCV RdRp have been described, including a promising series of benzothiadiazine derivatives which have been shown to efficiently block viral RNA synthesis in HCV replicon cell systems. Herein, the antiviral activity, mode of action, resistance profiling and therapeutic potential of the benzothiadiazine class of compounds for clinical development are explored.

Keywords: benzothiadiazines , NS5B , IFN-{alpha} , RdRp inhibitors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
F. Pauwels, W. Mostmans, L. M. M. Quirynen, L. van der Helm, C. W. Boutton, A.-S. Rueff, E. Cleiren, P. Raboisson, D. Surleraux, O. Nyanguile, et al.
Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors
J. Virol., July 1, 2007; 81(13): 6909 - 6919.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. A. Jones, L. E. Clancy, W. D. Rawlinson, and P. A. White
High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3019 - 3027.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Le Pogam, H. Kang, S. F. Harris, V. Leveque, A. M. Giannetti, S. Ali, W.-R. Jiang, S. Rajyaguru, G. Tavares, C. Oshiro, et al.
Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus.
J. Virol., June 1, 2006; 80(12): 6146 - 6154.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Mo, L. Lu, T. Pilot-Matias, R. Pithawalla, R. Mondal, S. Masse, T. Dekhtyar, T. Ng, G. Koev, V. Stoll, et al.
Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4305 - 4314.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
P. Simmonds
Genetic diversity and evolution of hepatitis C virus - 15 years on
J. Gen. Virol., November 1, 2004; 85(11): 3173 - 3188.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.